SS
ABOS icon

Steve Schonfeld’s Acumen Pharmaceuticals ABOS Stock Holding History

Steve Schonfeld’s Portfolio ABOS Stock Details ABOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-11,300
Closed -$26.7K – 2557
2026
Q1 		$26.7K Buy
+11,300
New +$28.8K ﹤0.01% 2032
2025
Q3 		– Sell
-15,929
Closed -$18.5K – 2154
2025
Q2 		$18.5K Buy
+15,929
New +$17.1K ﹤0.01% 1937
2024
Q3 		– Sell
-73,619
Closed -$178K – 1990
2024
Q2 		$178K Sell
73,619
-384,865
-84% -$1.23M ﹤0.01% 1825
2024
Q1 		$1.86M Sell
458,484
-103,058
-18% -$388K 0.01% 1018
2023
Q4 		$2.16M Sell
561,542
-83,570
-13% -$248K 0.01% 774
2023
Q3 		$2.68M Buy
+645,112
New +$3.99M 0.02% 731
2022
Q4 		– Sell
-152,429
Closed -$1.53M – 2539
2022
Q3 		$1.53M Buy
152,429
+36,400
+31% +$209K 0.01% 1005
2022
Q2 		$545K Buy
116,029
+29,486
+34% +$111K 0.01% 1320
2022
Q1 		$338K Hold
86,543
– – ﹤0.01% 1613
2021
Q4 		$585K Buy
+86,543
New +$951K 0.01% 1183

Other funds holding ABOS

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
KIA
Knollwood Investment Advisory Hunt Valley, Maryland $1.12B AUM 41.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Steve Schonfeld's ABOS Position: Q2 2026 in Review

Steve Schonfeld sold out of Acumen Pharmaceuticals (ABOS) in Q2 2026, closing a stake of 11,300 shares — an estimated $26.7K sold.

Steve Schonfeld first reported a position in ABOS in Q4 2021 and held it in 10 quarters. The position peaked at $2.68M in Q3 2023. 96 funds tracked by Wall St. Rank hold ABOS as of Q2 2026.

  • Steve Schonfeld reported no remaining Acumen Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Steve Schonfeld sold 11,300 Acumen Pharmaceuticals shares in Q2 2026, an estimated $26.7K.
  • Steve Schonfeld first reported a position in Acumen Pharmaceuticals in Q4 2021 and held it in 10 quarters.
  • Steve Schonfeld's Acumen Pharmaceuticals position peaked at $2.68M in Q3 2023.
  • 96 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q2 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.